VIA
RCUS icon

Virtus Investment Advisers’s Arcus Biosciences RCUS Stock Holding History

Virtus Investment Advisers’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$424K Buy
13,748
+1,084
+9% +$26.8K 0.1% 248
2026
Q1 		$274K Buy
12,664
+308
+2% +$6.65K 0.08% 296
2025
Q4 		$294K Buy
12,356
+187
+2% +$3.81K 0.08% 257
2025
Q3 		$165K Buy
12,169
+2,112
+21% +$22K 0.05% 361
2025
Q2 		$81.9K Buy
10,057
+485
+5% +$4.14K 0.03% 416
2025
Q1 		$75.1K Buy
+9,572
New +$111K 0.02% 451

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Virtus Investment Advisers's RCUS Position: Q2 2026 in Review

Virtus Investment Advisers increased its Arcus Biosciences (RCUS) stake by 8.6% in Q2 2026, buying an estimated $26.8K and bringing the position to 13,748 shares worth $424K. The position accounts for 0.1% of the portfolio, ranked #248.

Virtus Investment Advisers first reported a position in RCUS in Q1 2025 and has held it in 6 quarters since. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Virtus Investment Advisers held 13,748 shares of Arcus Biosciences worth $424K as of Q2 2026.
  • Virtus Investment Advisers bought 1,084 Arcus Biosciences shares in Q2 2026, an estimated $26.8K.
  • Arcus Biosciences made up 0.1% of Virtus Investment Advisers's portfolio in Q2 2026, its #248 holding.
  • Virtus Investment Advisers first reported a position in Arcus Biosciences in Q1 2025 and has held it in 6 quarters since.
  • 231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.